| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
| | | Three Months Ended June 30, | | | Six Months Ended June 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Numerator: | | | | | | | | | | | | | | | | |
| Net income (loss) | | $ | (15,386,729 | ) | | $ | (1,280,376 | ) | | $ | (13,966,367 | ) | | $ | 5,779,663 | |
| Accrued dividends on Series F Preferred Stock | | | (26,296 | ) | | | (52,038 | ) | | | (57,292 | ) | | | (119,688 | ) |
| Deemed dividends | | | (39,276 | ) | | | (3,677,811 | ) | | | (1,388,759 | ) | | | (4,734,143 | ) |
| Numerator for basic EPS - net income (loss) available to common stockholders | | | (15,452,301 | ) | | | (5,010,225 | ) | | | (15,412,418 | ) | | | 925,832 | |
| | | | | | | | | | | | | | | | | |
| Effect of convertible securities and liability classified equity instrument: | | | | | | | | | | | | | | | | |
| Accrued dividends on Series F Preferred Stock | | | — | | | | — | | | | — | | | | 119,688 | |
| Interest expense on convertible note payable | | | — | | | | — | | | | — | | | | 45,150 | |
| Gain on change in fair value of warrant liabilities | | | — | | | | — | | | | — | | | | (8,506,000 | ) |
| Numerator for diluted EPS - net loss available to common stockholders | | $ | (15,452,301 | ) | | $ | (5,010,225 | ) | | $ | (15,412,418 | ) | | $ | (7,415,330 | ) |
| | | | | | | | | | | | | | | | | |
| Denominator: | | | | | | | | | | | | | | | | |
| Denominator for basic EPS - weighted average shares | | | 59,552,801 | | | | 15,524,049 | | | | 56,383,308 | | | | 13,835,214 | |
| | | | | | | | | | | | | | | | | |
| Effect of dilutive securities: | | | | | | | | | | | | | | | | |
| Incremental shares for outstanding warrants (Series A, B and F) | | | — | | | | — | | | | — | | | | 4,837,593 | |
| Convertible note and accrued interest | | | — | | | | — | | | | — | | | | — | |
| Convertible Series F Preferred Stock | | | — | | | | — | | | | — | | | | 2,485,654 | |
| Convertible Series G Preferred Stock | | | — | | | | — | | | | — | | | | — | |
| Incremental unvested restricted stock units | | | — | | | | — | | | | — | | | | 68,797 | |
| Denominator for diluted EPS - weighted average shares | | | 59,552,801 | | | | 15,524,049 | | | | 56,383,308 | | | | 21,227,258 | |
| | | | | | | | | | | | | | | | | |
| Net income (loss) per common share - basic | | $ | (0.26 | ) | | $ | (0.32 | ) | | $ | (0.27 | ) | | $ | 0.07 | |
| | | | | | | | | | | | | | | | | |
| Net loss per common share - diluted | | $ | (0.26 | ) | | $ | (0.32 | ) | | $ | (0.27 | ) | | $ | (0.35 | ) |
|